Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Cassava Sciences

Cassava Sciences Stock Continues Showing Rising Relative Strength

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

Investors Business Daily

Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days

Cassava Sciences sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

Cassava Sciences Stock Clears Benchmark, Hitting 80-Plus RS Rating

Cassava Sciences sees its Relative Strength Rating move into the 80-plus level.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Cassava Sciences Stock Shows Big Jump In Its Relative Strength Rating

Cassava Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 70 to 87.

Investors Business Daily

12 Health Care Stocks Moving In Friday's Intraday Session

Gainers

Benzinga

Cassava Plummets After Refuting New Claims Around Data Tampering Investigation

Cassava refuted reports Friday that it received a "termination letter" from officials surrounding an investigation — and SAVA stock fell.

Investors Business Daily

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Over $2 Million Bet On Cassava Sciences; 4 Stocks Insiders Are Buying

Although US stocks closed mixed on Tuesday, there were a few notable insider trades.

Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27

Reuters Monkeypox Emergency Could Last Months, According To Experts

Benzinga

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

How Is The Market Feeling About Cassava Sciences?

Cassava Sciences's (NASDAQ:SAVA) short percent of float has risen 7.39% since its last report. The company recently reported that it has 11.46 million shares sold short, which is 31.54% of all regular shares that are available for trading.

Benzinga

Recap: Cassava Sciences Q1 Earnings

Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

What Are Whales Doing With Cassava Sciences

Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average annual return of 37.25%. Currently, Cassava Sciences has a market capitalization of $844.87 million.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

$1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 19.11% on an annualized basis producing an average annual return of 32.41%. Currently, Cassava Sciences has a market capitalization of $874.09 million.

Benzinga

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 242 companies hit new 52-week lows.

Benzinga

New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall

Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after

Benzinga

This Is What Whales Are Betting On Cassava Sciences

A whale with a lot of money to spend has taken a noticeably bullish stance on Cassava Sciences. Looking at options history for Cassava Sciences (NASDAQ:SAVA) we detected 14 strange trades.

Benzinga

Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 29.74% on an annualized basis producing an average annual return of 43.85%. Currently, Cassava Sciences has a market capitalization of $1.54 billion.

Benzinga

Here's How Much $100 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today

Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 26.48% on an annualized basis.

Benzinga

Check Out What Whales Are Doing With SAVA

Someone with a lot of money to spend has taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.